Riskpilot← Back to searchSign inGet full accessCSW Therapeutics AB
ABActiveOrg 5592235427Medicinaregatan 8 A Sahlgrenska Science ParkManufacture of medical and dental instruments and supplies · NACE 3250Est. 20192 employees
Revenue 2024
SEK 114K
EBITDA margin
-2241.5%
-98% vs 2023
Equity ratio
78.6%
Financial strength
Net profit 2024
SEK -2,7M
-90% vs 2023
| Revenue | SEK 114K | — |
| EBITDA | SEK -2,5M | -98% |
| Net profit | SEK -2,7M | -90% |
| Total assets | SEK 4M | +7% |
| Equity | SEK 3,2M | +10% |
| Employees | 2 | — |
Legal name
CSW Therapeutics AB
Org number
5592235427
Legal form
Aktiebolag
NACE code
3250 · Manufacture of medical and dental instruments and supplies
Founded
23 oktober 2019
Share capital
SEK 50 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Företaget är ett medicinteknikbolag med fokus på utveckling av icke-invasiv teknik för behandling av refraktär angina.
Address
Medicinaregatan 8 A Sahlgrenska Science Park
Email
mena.nadum@cswtherapeutics.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | −0 | 0 | 114 |
| Staff expenses | — | — | −94 | — | −1 360 |
| EBITDA | −1 | −8 | −591 | −1 284 | −2 547 |
| Depreciation & amort. | −0 | −0 | — | −118 | −97 |
| EBIT | −1 | −8 | −591 | −1 402 | −2 644 |
| Net financials | — | — | −0 | −20 | −57 |
| Profit before tax | −1 | −8 | −591 | −1 421 | — |
| Tax | −0 | −0 | — | −0 | — |
| Net profit | −1 | −8 | −591 | −1 421 | −2 701 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 49 | 123 | 484 | 3 760 | 4 027 |
| Equity | 49 | 42 | 251 | 2 864 | 3 163 |
| Long-term debt | 0 | 61 | 36 | 316 | 374 |
| Short-term debt | 0 | 20 | 197 | 580 | 489 |
| Total debt | — | 81 | 233 | 896 | 863 |
EBITDA margin
-2241.5%
This company
15.8%
Market median
-14287% vs market
20202024
Equity ratio
78.6%
This company
38.2%
Market median
+106% vs market
20202024
Return on equity
-85.4%
This company
18.4%
Market median
-564% vs market
20202024
Net profit margin
-2377.3%
This company
8.1%
Market median
-29449% vs market
20202024
Asset turnover
0.03×
This company
1.12×
Market median
-97% vs market
20202024
Debt / equity
0.27×
This company
0.62×
Market median
+56% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-10-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
FL Chief Executive Officer | Chief Executive Officer | 2024 |
| Audit | 2024 | |
MN Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Board of Directors | 2024 | |
| Former (1) | ||
| Deputy Board Member | 2022 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of CSW Therapeutics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Filip Ludwig Peters | Chief Executive Officer | 0 companies |
| Hans Christer Viking Andersson | Audit | 0 companies |
| Mena Nadum | Chief Executive Officer | 0 companies |
| Tor Peters | Board of Directors | 0 companies |
| Jens Wilhelm Peters | Deputy Board Member | 0 companies |